$ISRG

Ladd Amy L sold $180K of ISRG

Ladd Amy L sold 472 shares of INTUITIVE SURGICAL INC (ISRG) at an average of $381.15 ($379.00–$393.10, $0.18M total) across 2 trades over 2026-08-10 to 2026-08-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Ladd Amy L
Published Aug 11, 2026, 9:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 10:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ISRG
Neutral
high confidence
Mentioned
$ISRG
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ISRGNeutralLow
01

Why it matters

The only new information is the disclosed sale size, timing, and that it was executed under a pre-arranged 10b5-1 plan; there is no guidance, litigation, product, or financial update.

02

Market read

Routine 10b5-1 insider selling is typically low-signal for price, so it is unlikely to drive a durable repricing without additional company catalysts.

03

What to watch

The filing does not state reasons for sale, and the post-transaction holdings remain small (179 shares), reducing interpretability versus larger insider positions.

Relevance 3/10Novelty 2/10Timing: filed 2026-08-11, covering sales on 2026-08-10 to 2026-08-11

Background

The article is an SEC Form 4 insider transaction disclosure for Intuitive Surgical (ISRG) by director Ladd Amy L.

Company-level read

Ticker impact

$ISRGNeutralHigh confidence
Context

Form 4 shows director Ladd Amy L sold about $179.9K of ISRG shares in two open-market trades under a 10b5-1 plan.

Expected impact

Likely minimal immediate impact; any reaction would be more sentiment-driven than fundamental.

Evidence & confidence

The filing is an SEC Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new company-specific operational or financial information.

Market effects

No sector-level implications; this is company-specific insider trading with no stated business change.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with private concerns, so traders may watch for follow-on sales or other negative disclosures.

Key entities

  • ISRG

    Intuitive Surgical, the company whose shares were sold by a director.

  • Ladd Amy L

    Director who executed two open-market sales totaling $179,903.20 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ISRGHighAI 8/10

Intuitive receives CE mark for transvaginal use of da Vinci SP system

Intuitive Surgical (ISRG) received CE mark approval for its da Vinci SP system for transvaginal gynecological procedures in Europe, expanding its use in women's health. The system, already approved for other surgeries, allows single-incision operations, potentially improving recovery and outcomes. It is also approved in the US, Japan, and Korea.

$ISRGHigh

Intuitive announces expanded indication for da Vinci SP in Europe

Intuitive (ISRG) received CE mark approval for transvaginal gynecologic procedures using the da Vinci SP system in Europe, expanding its applications. The approval allows for less invasive options and potentially better recovery experiences. The system is already approved in the US, Japan, and Korea for various procedures.

$IARTMedAI 8/10

Q2 Earnings Outperformers: Integra LifeSciences (NASDAQ:IART) And The Rest Of The Surgical Equipment & Consumables - Specialty Stocks

Integra LifeSciences (IART) reported flat Q2 revenue of $418.8M, meeting expectations. Teleflex (TFX) saw 28.9% revenue growth, beating estimates. LeMaitre (LMAT) missed expectations with 9.6% growth. Intuitive Surgical (ISRG) reported 18.5% growth, beating estimates. All stocks declined post-earnings, with IART down 17.7%, TFX flat, LMAT down 24.9%, and ISRG down 12.3%.

$ISRGMed

ISRG Stock Trading at its Cheapest in 10 Years: Should You Buy Now?

Intuitive Surgical (ISRG) trades at its lowest valuation in a decade, with a forward P/E of 30.26x, below its 10-year median. Despite a 40% decline, Q2 2026 revenue grew 19% to $2.89B, and EPS rose 28%. Management maintained 2026 da Vinci procedure growth forecast at 13.5-15.5%, citing international growth but noting U.S. and China uncertainties. ISRG's product pipeline includes da Vinci 5 and Ion systems, with innovations like SP procedures up 61%. Shares lag industry and sector, down 15% in 3